Welcome to our dedicated page for ATAI Life Sciences N.V. Common Shares news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V. Common Shares stock.
ATAI Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental health disorders. Based in the United States and Germany, ATAI leverages a decentralized, technology- and data-driven platform to serve millions suffering from mental health challenges. The company’s mission is to develop innovative treatments that address significant unmet medical needs, leading to paradigm shifts in mental health care.
ATAI's product pipeline includes promising candidates such as COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. These candidates are designed to treat conditions such as depression, anxiety, addiction, and other mental health disorders.
Recently, ATAI announced positive results from its Phase 1 study of EMP-01, the R-enantiomer of MDMA. The study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EMP-01. Involving 32 healthy participants, the study showed that EMP-01 was well-tolerated with no severe adverse events. The PK profile was dose-proportional, and PD measures indicated significant, consistent, and dose-dependent changes. These promising results might pave the way for EMP-01’s further clinical development.
ATAI Life Sciences is committed to efficient drug development by pooling resources, expertise, and best practices across its portfolio. This approach helps mitigate risks and accelerates the development of impactful, evidence-based treatments. The company’s vision is to heal mental health disorders, enabling everyone to live a more fulfilled life.
For more information, visit their official website at www.atai.life.
atai Life Sciences (Nasdaq: ATAI), a biopharmaceutical company focused on mental health treatments, will participate in key healthcare conferences this June. The BIO International Conference will feature a company presentation on June 16 from 2:45 PM to 3:15 PM ET. Following this, the H.C. Wainwright 1st Annual Mental Health Conference is scheduled for June 27 at 12:00 PM ET. Both events aim to highlight atai's innovative approaches to mental health disorders. Archived webcasts will be available on atai's website for further insights.
atai Life Sciences reported significant progress in its clinical pipeline for Q1 2022, including dosing the first subject in the Phase 1 KUR-101 trial and launching its drug discovery engine, Invyxis. With a cash position of $335 million, the company is well-funded to continue its initiatives. Key milestones anticipated for 2022 include data from the Phase 2 PCN-101 study for treatment-resistant depression and more Phase 1 and 2 trial initiations. However, R&D expenses surged to $15.5 million, contributing to a net loss of $36.9 million this quarter.
atai Life Sciences (Nasdaq: ATAI) is a clinical-stage biopharmaceutical company focused on addressing mental health disorders. The firm will announce its Q1 2022 financial results and business updates on May 16, 2022. A video interview with management will be available at 8:30 a.m. (ET) for investors to gain insights into the company's performance. Founded in 2018, atai combines funding, technology, and expertise to develop innovative therapeutics, including psychedelic therapies, aimed at transforming mental health treatment.
atai Life Sciences N.V. (Nasdaq: ATAI) will announce its first-quarter 2022 financial results on its investor relations website. A video interview featuring CEO Florian Brand, CSO Srinivas Rao, and CFO Greg Weaver is set for May 9, 2022, at 8:30 A.M. Eastern Time. atai focuses on transforming mental health treatment through innovative therapeutics, particularly in the areas of depression, anxiety, and addiction. Founded in 2018, it aims to address unmet needs in mental health care.
atai Life Sciences (Nasdaq: ATAI) will present at the Benzinga Psychedelics Conference on April 19, 2022, from 1:10 p.m. to 1:40 p.m. ET. This event will take place both in person and virtually. Investors can access the presentation via a provided conference link.
Founded in 2018, atai focuses on innovative therapies for mental health disorders including depression and anxiety. The company's goal is to heal mental health issues globally, utilizing a unique business model that integrates funding, technology, and expertise.
atai Life Sciences (Nasdaq: ATAI) announced a webcast on March 30, 2022, at 8:30 AM ET to discuss its fourth quarter 2021 financial results and provide a business update. The live and archived webcast can be accessed through this link. Founded in 2018, atai focuses on innovative therapeutics for mental health disorders like depression and anxiety.
atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatment, will participate in two investor conferences in March 2022. The first is the Citi Winter Biotech Virtual Bus Tour on March 22, from 11:00 a.m. to 11:40 a.m. ET. The second is the Maxim Group 2022 Virtual Growth Conference, occurring from March 28 to March 30. Archived webcasts will be accessible via the Events section on atai's website.
atai Life Sciences has announced a $500,000 donation to the Multidisciplinary Association for Psychedelic Studies (MAPS) through its philanthropic arm, atai Impact. This funding will support MAPS' operations and its Health Equity Program, aimed at increasing diversity and inclusivity in psychedelic healthcare. The donation reflects a collaborative effort to address the global mental health crisis worsened by the pandemic. Florian Brand, CEO of atai, emphasized the importance of innovation and collaboration in tackling these challenges.
atai Life Sciences N.V. (Nasdaq: ATAI) will participate in the Aegis Conference on February 24, 2022, at 11:30 a.m. ET. The conference will be virtual, and interested parties can access the presentation via this link.
Founded in 2018, atai focuses on innovative therapeutics for mental health disorders, including depression and anxiety. Their approach emphasizes psychedelics and drugs with unique safety profiles, aiming to expedite the development of effective treatments.
Atai Life Sciences announced FDA clearance for a clinical drug-drug interaction study on PCN-101 (R-ketamine), aimed at treating treatment-resistant depression (TRD). The study will assess pharmacokinetics when used with other medications and will complement an ongoing Phase 2a trial in Europe. PCN-101 offers potential rapid action and better safety compared to traditional antidepressants. An estimated 100 million people globally suffer from TRD, leading to increased healthcare costs. The study reflects atai's commitment to addressing significant mental health needs.
FAQ
What is the current stock price of ATAI Life Sciences N.V. Common Shares (ATAI)?
What is the market cap of ATAI Life Sciences N.V. Common Shares (ATAI)?
What is ATAI Life Sciences N.V.?
Where is ATAI Life Sciences based?
What are some of ATAI Life Sciences' key products?
What recent achievement has ATAI announced?
What is EMP-01?
What is the mission of ATAI Life Sciences?
How does ATAI Life Sciences accelerate drug development?
What is the vision of ATAI Life Sciences?
How can I get more information about ATAI Life Sciences?
